Highly accomplished Ph.D. medicinal chemist with 20 years of experience in the pharmaceutical industry with proven record of rapidly advancing programs from lead generation through lead optimization to pre-clinical development. Previously at Enliven, Pfizer, and Array Biopharma

Joey received his PhD in Computer Science from the University of Colorado where he focused on the intersection of AI and Cancer Genomics. From this, Joey developed the founding IP for Arpeggio. Following positions at Merck and Forma Therapeutics, Joey founded Arpeggio raising over $60M from top life-sciences investors.

20+ years industry experience in small molecule drug discovery project leadership from hit finding to clinical candidate nomination resulting in the nomination of multiple development candidates currently undergoing clinical evaluation. Previously leadership roles at Enliven, Pfizer, Blueprint, and Novartis

Tim received his PhD in Molecular Biology from the University of Colorado where he focused on mechanisms or eukaryotic transcription. After doing his postdoctoral fellowship at Harvard Med, Tim founded Arpeggio to drug transcription factors. Tim leads Arpeggio's transcriptomic drug screening efforts and discovery biology efforts around NRF2.

I’m excited to contribute as a Senior Scientist or Translational Biology lead in drug discovery—owning biology strategy, partnering tightly with chemistry and clinical, and differentiating programs through robust assays, fit‑for‑purpose models, and crisp decision‑making.Scientific and Laboratory Expertise Protein purification from bacteria, insect, and human expression platforms employing both FPLC and affinity chromatography platforms. Experienced enzymologist, developed and ran multiple biochemical assays (esp. kinase assays). Experience with crystallography and using Pymol to view structures. Cloning using various techniques including plasmid subcloning molecular cloning, and RT-PCR. Proficient in collection of DNA/RNA from human cell culture for use in PCR gene isolation. Human cell culture of immortalized lines and primary cells. Stable cell line generation. Development, optimization and validation of multiple mechanistic and functional cell-based assay development employing a variety of technologies including HTRF, in-cell western, high-throughput microscopy, flow cytometry and nanoBRET. Accelerated mutagenesis screens to identify novel on-target resistance mechanisms. Highly skilled microscopist- wide-field, confocal, and TIRF imaging techniques.

Ardeshir received his PhD from UNC Chapel Hill where he studied molecular dynamics of diseased proteins. He went on to do his postdoctoral fellowship at AstraZeneca and then worked as an investigator at Novartis. Ardeshir leads Arpeggio's computational chemistry efforts, bridging the gap between AI, biology, and medicinal chemistry.

Dave has over 20 years of experience running and managing molecular biology labs at Harvard Medical School, Martek Biosciences, and the University of Colorado. At Arpeggio, Dave connects lab operations to our drug discovery initiatives.

Jeff received his BS in Bioengineering - Cell & Tissue Engineering from UC Berkeley College of Engineering. Jeff brings an extensive background of leading development teams responsible for deploying and maintaining integrated systems. At Arpeggio, he manages method development and support of our platform and R&D pipelines.

Jenna received her PhD from the University of Colorado where she focused on the mechanisms of RNA Pol II mediated transcription and collaborated with Syros Pharmaceuticals on a novel CDK7 inhibitor. At Arpeggio, Jenna focuses on target discovery and validation for transcriptional addiction mechanisms in cancer.

Leah received her PhD in Biochemistry from the University of Colorado where she used microscopy and genomics to study the role of zinc in transcriptional regulation. Prior to grad school, Leah worked at MA General Hospital where she screened cancer cell lines to identify novel therapeutics. At Arpeggio, Leah focuses on scaling and automating drug screening efforts.

Reo received his MA in Bioengineering from UC San Diego where he studied systems biology. Reo came to us from a drug discovery start-up and at Arpeggio, he works at the interface of drug screening, automations, and assay development.

Richard received his PhD from the University of East Anglia (UK) where he studied disrupting protein-protein interactions. Richard previously worked on targets for oncology and rare diseases. At Arpeggio, Richard works on advancing hit compounds to leads for drug discovery.